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1. Abstract 
 
Tumor blood vessels display characteristics that distinguish them from vessels in 
healthy tissues. They form a hyperdense meshwork and are in general less functional 
than normal blood vessels. This is due to decreased pericyte coverage, unstable 
perfusion and increased vascular permeability. All these features lead on the one hand 
to insufficient nutrient and oxygen delivery and on the other hand impede the uniform 
targeting of the tumor with drugs. 
We show that B-Raf, the main activator of Erk in the MAP kinase signaling cascade, 
contributes to hyperpermeability of blood vessels in a tumor environment. We 
analyzed a mouse with conditional knock-out of B-Raf in endothelial cells and 
hematopoietic cells, B-Raf EC KO. Those mice show accelerated tumor growth of LLC-1 
allografts. The tumors show decreased necrotic areas, however, the number of blood 
vessels within the tumor stays unchanged. We hypothesize, that the functionality of 
tumor vessels in B-Raf EC KO mice is restored and that the vasculature is normalized 
compared to control, which could lead to the observed accelerated tumor growth.  
We find that perfusion of vessels is not affected in B-Raf EC KO mice. In addition 
pericyte coverage is unchanged compared to control. With the so-called Miles Assay, 
an in vivo-assay that determines permeability of skin blood vessels, we could 
demonstrate that the B-Raf EC KO mice are more resistant to VEGF induced 
permeablity compared to control mice shown by a reduced extravasation of Evans 
Blue. Furthermore we show that B-Raf EC KO mice have a lower basal level of vessel 
permeability in the LLC-1 tumor compared to control mice. In vitro we determine the 
barrier function of the endothelial cells by performing an impedance measurement of 
an endothelial cell monolayer. We find that B-Raf KO endothelial cells show a lower 
permeability specifically after VEGF stimulation than control cells. To rule out a 
possible role for the myeloid lineage, which is deleted for B-Raf in the B-Raf EC KO 
mice, we analyzed the growth of LLC-1 allografts in mice lacking B-Raf specifically in 
the myeloid compartment. In this mice tumor growth is unchanged. 
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Our results indicate a role for endothelial B-Raf in contributing to a state of 
hyperpermeability in tumor blood vessels. This could be of special relevance in tumor 
therapy, where specific inhibitors for B-Raf are currently in clinical trials. 
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1. Zusammenfassung 
 
Tumorblutgefäße zeichnen sich durch einige Eigenschaften aus, die sie von Gefäßen in 
anderen Geweben unterscheiden. Sie formen ein übermäßig dichtes Netzwerk, sind 
aber generell weniger funktionell als normale Blutgefäße. Das resultiert aus geringer 
Perizytenanlagerung, unregelmäßiger Durchblutung und hoher Permeabilität. Diese 
Charakteristika sind zum einen für den ungenügenden Transport von Nährstoffen und 
Sauerstoff verantwortlich, zum anderen erschweren sie es, den Tumor gleichförmig 
medikamentös zu behandeln. 
Wir können nun zeigen, dass B-Raf, der Hauptaktivator von Erk im MAP Kinase 
Signaltransduktionsweg, zur Hyperpermeabilität von Blutgefäßen in einem 
Tumorumfeld beiträgt. Wir haben einen Mausstamm mit einem konditionellen Knock-
out von B-Raf in Endothelzellen untersucht; B-Raf EC KO. Diese Mäuse zeigen 
beschleunigtes Tumorwachstum von injizierten LLC-1 Allografts. In den Tumoren 
wurden weniger nekrotische Bereiche gefunden, die Anzahl an Blutgefäßen ist aber 
gleich. Wir haben die Hypothese aufgestellt, dass die Funktionalität von 
Tumorblutgefäßen wieder hergestellt ist und das Gefäßsystem normalisiert ist im 
Vergleich zur Kontrolle. Diese Annahme stützt auch das beschleunigte 
Tumorwachstum, das wir in den Mäusen beobachten. 
Wir konnten zeigen, dass die Durchblutung der Gefäße in B-Raf EC KO Mäusen nicht 
betroffen ist. Perizytenanlagerung war ebenfalls nicht verändert im Vergleich zur 
Kontrolle. Mit dem so genannten Miles-Assay, ein in vivo Test, der die Permeabilität 
von Blutgefäßen der Haut bestimmt, konnten wir zeigen, dass B-Raf EC KO Mäuse 
Defekte in der Regulierung ihrer sogenannten Barriere-Funktion nach Stimulation mit 
VEGF haben. Außerdem haben B-Raf EC KO Mäuse ein geringeres basales 
Permeabilitätslevel ihrer Tumorgefäße. In vitro führten  wir eine Impedanzmessung 
durch, die Informationen über die Barriere-Funktion der Zellen gibt. Das Ergebnis ist, 
dass B-Raf KO Endothelzellen ihre Permeabilität nach einem VEGF Stimulus nicht 
hinauf regulieren können. Die Zellen haben also den selben Defekt, den wir auch in 
vivo durch den Miles Assay zeigen konnten. 
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Um eine mögliche Beteiligung der myeloiden Zelllinie, die in B-Raf EC KO Mäusen 
ebenfalls für B-Raf deletiert ist, auszuschließen, haben wir das Wachstum von LLC-1 
Allografts in Mäusen defizient für B-Raf spezifisch im myeloiden Kompartment 
analysiert. In diesen Mäusen ist das Wachstum von LLC-1 Tumoren nicht verändert. 
Unsere Resultate weisen darauf hin, dass B-Raf in Endothelzellen zu einer erhöhten 
Permeabilität in Tumorblutgefäßen beiträgt. Dieses Ergebnis könnte von großer 
Relevanz in der Tumortherapie sein, wo spezifische B-Raf Inhibitoren bereits in 
klinischen Studien getestet werden. 
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2. Introduction 
 
2.1. Architecture of blood vessels  
 
In vertebrates, blood vessels form a tight meshwork of arteries, veins and capillaries 
through the whole organism,  allowing  all tissues and peripheric areas of the body to 
be perfused with blood and thereby supplied with oxygen and nutrients. Immune cells, 
but also cancer cells use blood vessels as highways on which they can move through 
the whole organism.  
The supply of nutrients and oxygen as well as the clearance of CO2 and metabolic 
waste products from the tissues occurs via microvascular capillaries, the most 
abundant type of vessel. They consist only of a tube of endothelial cells (ECs) 
surrounded by a basement membrane secreted by the endothelial cells themselves as 
well as from vessel specific supporting cells such as vascular smooth muscle cells 
(vSMCs) and pericytes. Pericytes that are embedded in the basement membrane 
stabilize the endothelial tube and keep it in a quiescent state. Capillaries have organ-
specific characteristics such as fenestrations that occur in kidney and in endocrine 
glands. Arteries and veins are larger vessels that transport blood with high efficiency 
for long distances within the body. Arteries transport oxygenated blood from the heart 
into smaller arterioles and into the capillary bed of the body. Veins transport the 
deoxygenated blood from peripheric tissues back to the heart and finally to the lungs, 
where the blood is reoxygenated. Arteries and veins both consist of three different 
layers: The Intima, which is the endothelial cell tube with an internal elastic lamina; the 
Media, made out of smooth muscle cells that stabilize the EC tube surrounded by an 
external elastic lamina; and the Adventitia that consists of fibroblasts and extracellular 
matrix. In contrast to the loose pericyte coverage found in capillaries, the larger 
arteries and venes are highly covered with multiple layers of vascular smooth muscle 
cells. Arterioles and venules are vessels of medium size (Fig.1.) [1-2]. 
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Fig.1. modified from [1]. Overview of different types of blood vessels. 
 
 
2.2. The formation of blood vessels: vasculogenesis and angiogenesis 
 
Angiogenesis and vasculogenesis are the two types of blood vessel growth. 
Vasculogenesis refers to primary formation of the blood system in the developing 
embryo, whereas angiogenesis is the growth of blood vessels from preexisting ones. 
The formation of blood vessels is under tight regulation. Angiogenic and vasculogenic 
growth requires precise coordination of cell proliferation, differentiation, migration, 
matrix remodeling and various signaling processes between different cell types. After 
embryonic development angiogenesis occurs in wound healing, growth of tissues (e.g. 
fat tissue), tissue remodeling (e.g. endometrium) and in a number of pathologies. 
Vasculogenesis is a completed process after embryogenesis.  
In vasculogenesis the precursors of endothelial cells, the angioblasts, form the vascular 
plexus that subsequently develops into primitive blood vessels. The most prominent 
factor in vasculogenesis and angiogenesis is vascular endothelial growth factor (VEGF). 
VEGF is crucial for the generation of blood vessels, since mice heterozygous for VEGF-A 
or its receptor (Flk1, also called VEGFR2) die in utero because of the lack of blood 
vessels and hematopoietic cells[3-5]. Mice lacking VEGF receptor 1 (VEGFR1) are able 
to form angioblasts, but the assembly of vessels is impaired [6]. Newly developed 
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vessels become stabilized by the recruitment of mural cells and by the establishment 
of a basement membrane. VEGF signaling stimulates ECs to secrete platelet derived 
growth factor B (PDGF-B), which in turn stimulates migration and proliferation of 
pericytes [7]. Also other factors secreted by endothelial cells, such as S1P-1 and 
angiopoietins, are implicated in the attraction of pericytes [8]. Mural cells produce 
Ang1 and thereby stabilize vessels and prevent them from leaking. ECM formation is 
driven by TGF-ß1 which is secreted by ECs [1, 9]. 
Once the first blood vessels are formed, further growth of the vascular system occurs 
by angiogenesis. In angiogenesis, new vessels form from pre-existing ones through 
sprouting. Angiogenesis is initially stimulated by the secretion of VEGF, induced in turn 
by the oxygen sensor HIF-1 whenever low levels of oxygen are detected within the 
tissue [10]. Together with other pro-angiogenic factors such as FGF [11], Ang-2, and 
under certain conditions also Ang-1 [12], VEGF stimulates ECs that are incorporated in 
blood vessels to change their state from quiescent to active, rendering them able to 
proliferate and to migrate.. First, the ECM and basement membrane need to be 
remodeled locally to give the forming tip cell the opportunity to grow out of the 
preexisting vessel. The tip cell is the leading endothelial cell sprouting out of the vessel. 
It forms dynamic filopodia that scan the environment for further growth factors, and 
therefore guides the proliferating stalk cells, ECs forming the stem of the sprout, to 
sites were high levels of VEGFA are secreted [2]. To form a perfused vessel, the tip cell 
needs to contact another vessel or tip cell. At this point, strong cell-cell contacts are 
established, mural cells are recruited, ECM is deposited and a vessel lumen is 
generated. 
 
 
2.3. The role of pericytes in the vascular system 
 
In an adult organism, endothelial cells are usually in a quiescent state that is 
maintained by signaling from pericytes and vascular smooth muscle cells (vSMCs). 
Pericytes are attracted to developing blood vessels by PDGF-B secreted from ECs and 
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wrap around the endothelial cell tube, regulating different vessel parameters [14] 
(Fig.2). Pericytes can contract or relax depending on outside stimuli and therefore 
regulate vessel diameter and capillary blood flow [13]. In general, vessels that are 
under high blood pressure show more pericyte coverage [14]. Pericytes are also 
necessary to establish the blood-brain barrier, which indicates an essential role in 
vessel integrity. Besides providing mechanical stability to the vessel, the pericytes 
contribute to maintaining ECs in a non-proliferative and non-migratory state through 
direct signaling. 
 
 
Fig.2. Modified from [15]. Signaling pathways in pericyte attraction and vessel 
stabilization 
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One important paracrine signaling pathway is that of angiopoietins and their receptors 
Tie. Ang-1 produced by pericytes maintain the quiescent state and promote survival of 
ECs, whereas Ang-2 derived from the ECs in contrast loosens the contact between ECs 
and pericytes and can eventually lead to an active, sprouting state of the endothelial 
cells in the presence of VEGF [13] (Fig2). Another signaling pathway that influences 
endothelial/pericyte interaction is the Sphingosine-1 phosphate (S1P) pathway. 
Produced by hematopoietic cells and platelets, S1P supports trafficking of the adhesion 
molecule N-Cadherin to adherens junctions in ECs, thereby stabilizing the contact 
between ECs and pericytes. The differentiation of pericytes is mainly achieved through 
TGF-β that is mobilized by the endothelial cells.  Taken together, pericytes are 
important regulators of blood vessel maintenance and growth. 
 
 
2.4. Characteristics of tumor blood vessels 
 
In normal tissue, a very sensitive balance between pro- and anti-angiogenic factors 
ensures that blood vessels are correctly formed and matured and that angiogenesis 
occurs only in a controlled and restricted manner. Many diseases like obesity, 
rheumatoid arthritis, diabetic retinopathy and solid tumors require angiogenesis. 
Pathological angiogenesis is very disorganized and uncontrolled. This holds also true 
for blood vessel formation in solid tumors. A tumor larger in size than 2mm3 can no 
longer be provided with oxygen by diffusion, wherefore tumor blood vessels need to 
be formed [16]. Due to the imbalance of angiogenic factors produced during tumor-
induced angiogenesis, vessels formed under pathological conditions are usually 
abnormal in their structure and function. Tumor blood vessels have various features 
that distinguish them from vessels in normal tissue. Many tumors produce large 
amounts of angiogenic stimulators, resulting in hyperactive vessel growth without 
stabilization of the newly formed vessels [8].Tumor vasculature is characterized by an 
abnormally high vessel density, because anti-angiogenic factors that restrict growth of 
sprouts are missing. Despite their number, however, these vessels are less functional 
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and don’t supply the tumor efficiently with oxygen and nutrients. The resulting hypoxia 
leads to a vicious circle of production of more angiogenic factors and, as a result, to 
even more anomalous vessels [17]. The architecture of tumor blood vessels is usually 
described as tortuous, disorganized and irregular. Because stabilizing factors are not 
present, tumor blood vessels may lack pericyte coverage and even a basement 
membrane. Interestingly, VEGF itself leads to impaired pericyte coverage of vessels. 
Mechanistically, VEGF binds to the VEGFR-2 expressed on the pericyte/vSMC and 
inhibits PDGFRβ signaling by forming a VEGFR-2/PDGFRβ heterodimer [18]. Endothelial 
cells can be very abnormal in the tumor with gaps in between cells, fenestrations and 
impaired signaling. Usually, tumor blood vessels are also hyperpermeable which leads 
to a very bad nutrient supply and high rates of necrosis in the inner part of the tumor. 
This is linked to the enhanced permeability and retention (EPR) effect, which describes 
the retention of molecules of more than 50kDa in size specifically in tumor tissue [19] – 
a phenomenon which based on the abnormally high permeability of tumor vessels 
(Fig.3.). 
The vessels in a tumor display great heterogeneity. In some regions so-called blood 
lakes form, where big hollow spaces in the tumor are filled with blood. These “lakes” 
are not part of the circulation and don’t participate in nutrient supply. In addition, the 
direction of the blood flow may vary, since there is no clear distinction between 
arteries and veins in the tumor. All of these defects result in an acidic, hypoxic 
environment that favors  
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Fig.3. Modified from [20]and [21]. a. normal vs. b. tumor blood vessels. 
malignancy and metastasis and negatively affects the delivery of chemotherapeutics 
[21-24]. 
 
 
2.5. Anti-angiogenic therapy 
 
Since it became clear that all solid tumors, irrespective of their  origin, need 
angiogenesis, tumor blood vessels have been a promising target for cancer treatment. 
The initial approach was to inhibit further vessel growth and/or destroy existing tumor 
vessels to starve the cancer cells and ideally lead to tumor shrinkage [25]. VEGF is the 
most important factor in promoting tumor angiogenesis and it is overexpressed at high 
frequency in many cancers. Therefore, anti-VEGF therapy is the most tested anti-
angiogenesis therapy, although other potential targets have been investigated. A 
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monoclonal antibody against VEGF is now approved for the treatment of several types 
of cancer. So far, anti-angiogenic treatment has achieved only moderate success.  In 
patients, it delays tumor progression for a few months at best [26-27]. The reason for 
this rather disappointing results is that tumors can adapt rapidly to anti-angiogenic 
therapy and evolve strategies for resistance, for example by upregulation of 
alternative pro-angiogenic signaling pathways, recruitment of bone-marrow derived 
cells that stimulate angiogenesis, enhanced pericyte coverage, and metastasis [28]. 
This means that anti-VEGF therapy can even drive tumor progression. On the other 
hand, it has also been shown that anti-angiogenic therapy can be quite successful in 
the combination with chemotherapy. 
Many abnormalities of the tumor vasculature are direct or indirect effects of the high 
level of VEGF signaling in the tumor. Therefore it has been hypothesized that anti-
VEGF therapy might also lead to a normalization of tumor vessels [23]. This 
normalization ideally would lead to more functional and less leaky vessels  able to 
transport blood into all parts of the tumor equally well.  As a consequence, primary 
tumor growth would not be restricted, but the efficacy of chemotherapy could be 
enhanced because of increased delivery of chemotherapeutic agents. These drugs 
could then act on all parts of the tumor and therefore lead to uniform shrinkage [26-
27]. 
In conclusion, anti-VEGF therapy can have different effects on tumor growth 
depending on the origin, on the genetic setup and on the VEGF-dependence of a 
tumor. 
 
 
2.6. Vascular permeability 
2.6.1 Transcellular and Paracellular molecular transport  
 
The most fundamental functions of blood circulation - distributing oxygen and 
nutrients in the organism and giving immune cells a highway which they can enter and 
leave at distant body sites - are highly linked with vessel permeability. Endothelial 
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transport can occur in a transcellular or paracellular way. Solutes with a radius up to 
3nm can move passively through the endothelial barrier by the paracellular route, i.e. 
just by diffusing between 2 endothelial cells. Active transport of macromolecules 
occurs via the transcellular route, which means crossing an endothelial cell in a vesicle 
[29] (Fig.4.). Transcytosis occurs following the interaction of plasma proteins with 
specific docking molecules on caveolae on the surface of endothelial cells 
[30].Transcellular transport is regulated by cellular adhesive forces, whereas 
paracellular transport is regulated by modifying interendothelial junctions (IEJs).  
Inflammatory effectors like Thrombin, VEGF, bradykinin, histamine and others modify 
permeability via disrupting the organization of IEJs and integrin-ECM complexes. This 
opens intercellular gaps and allows passage of proteins [31]. The composition of the 
extracellular matrix (ECM) and of the basement membrane has also an impact on 
vessel permeability, as well as the interactions between ECs and ECM influence overall 
permeability. Vessels from different organs and different size have of course individual 
differences in those parameters and in permeability. 
 
Fig.4. [32]. Paracellular transport (left) vs. transcellular transport (right). 
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2.6.2 The role of Adherens junctions in vascular permeability 
 
Adherens Junctions, which are mediated by the homophilic interaction among VE-
Cadherin (VEC) molecules on different endothelial cells are necessary for 
establishment of a barrier function.. Deletion of VEC in mice leads to lethality due to 
an immature vasculature. Tight Junctions and Gap Junctions are also necessary for the 
endothelial barrier formation, although their role is less studied so far [33]. 
Various signaling pathways regulate endothelial permeability. Most of them stimulate 
the formation or disruption of IEJs. Various modifications of VEC that have been 
discovered influence vascular permeability. For example, phosphorylation of certain 
residues in VEC or one of its adaptor proteins, β-catenin, modulate the strength of 
adherens junctions. Furthermore, internalization of VEC after VEGF stimulation, or 
cleavage of VEC by different metalloproteases (MMPs) has been shown to lower the 
endothelial barrier function. Conversely, high cellular levels of cyclic adenosin 
monophosphate (cAMP) promote barrier function by strengthening VEC structures. 
 
 
2.6.3 Factors modifying vascular permability 
 
VEGF, which was also identified as vascular permeability factor (VPF), is known to 
stimulate vascular permeability via its receptor Flk-1 [34]. Flk-1 activates many 
signaling pathways, amongst them Ras, PI3K, PKC and PLC [35]. It is yet unclear which 
of these pathways is involved in regulating vascular permeability. Conflicting results 
have been reported, for instance, on the role of MEK : Wu et al. showed that VEGF 
induced permeability of rat venules is blocked by MEK inhibition [36]. In contrast, in 
frog microvessels MEK inhibition had no effect [37]. However, it is known that VEGF 
stimulates vascular permeability via elevating intracellular Ca2+ levels which in turn 
leads to the internalization of VEC [38].As a consequence, cell-cell contacts loosenand 
paracellular permeability increases.[38] . Additionally, VEGF induced elevated Ca2+ 
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levels lead to increased vesicle fusion and therefore increased transcellular 
permeability [33]. 
Other permeability stimulating factors, such as the bacterial endotoxin LPS, the 
coagulation factor Thrombin and the cytokine TNF-α, induce vascular permeability also 
by elevating Ca2+ levels, although the second messengers vary between the different 
signaling pathways and are not yet fully understood. Factors opposing permeability are 
S1P and Ang-1, which lead to assembly of AJs and thereby strengthening of barrier 
function. [33]. .  
 
 
2.7. Tumor associated macrophages - TAMs 
 
Immune cells are reported to have different roles in tumorigenesis.  For macrophages 
it is known that the different subclasses M1 and M2 have opposing effects. Classically 
activated M1 macrophages respond to stimuli like LPS or IFN-γ. They produce pro-
inflammatory cytokines and kill microorganisms and tumor cells and are therefore 
tumor repressing [39].The alternatively activated population of M2 macrophages 
responds to anti-inflammatory chemokines such as IL-4 and IL-10. M2 macrophages 
participate in anti-inflammatory processes, Th1 immunity, tissue repair and 
angiogenesis and are therefore considered tumor-promoting [39-40]. Tumors actively 
recruit macrophages by secreting macrophage colony stimulating factor (M-CSF) and 
other attracting chemokines [41]. Tumor associated macrophages (TAMs) can have an 
M1 or M2 phenotype, depending on the signaling factors present in the tumor [42]. 
Usually, a high number of TAMs correlates with bad prognosis, which indicates that the 
majority of macrophages might be the tumor promoting M2 type in many tumors. 
Macrophages may promote tumorigenesis in different ways, for example by secreting 
matrix metalloproteases (MMPs) which enhance tumor invasiveness [43],  growth 
factors stimulating tumor cell growth , and/or pro-angiogenic factors such as VEGF and 
FGF which promote angiogenesis [41]. 
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A subpopulation of monocytes Tie2 expressing monocytes (TEMs),  has very high pro-
angiogenic potential. TEMs are attracted by tumor or Tumor-associated endothelial 
cells secreting Ang-2, [44], and enhance tumor angiogenesis by secreting angiogenic 
factors and MMP9, which leads to the release of growth factors from ECM [45-46].  
 
 
2.8. MAP kinase pathway 
 
The MAP kinase pathway is one of the major signaling pathways regulating cell 
proliferation, differentiation and apoptosis. The best-known mitogen-activated protein 
kinase pathway is the Ras – Raf – Mek – Erk pathway, activated by many extracellular 
stimuli including the binding of growth factors to receptor tyrosine kinases. Once the 
receptor is activated, the nucleotide exchange factor SOS is recruited to the plasma 
membrane and activates the small G-protein Ras. As a consequence, GDP is released 
from Ras, allowing the binding of GTP. GTP-loaded Ras can bind and thereby activate 
the serine/threonine kinase Raf. Subsequently, Raf activates its substrate MEK, which 
in turn phosphorylates and thereby activates ERK. Once ERK is activated, it can modify 
numerous target proteins in the nucleus as well as in the cytosol, thereby affecting cell 
motility, metabolism, differentiation, proliferation, survival or apoptosis. Since the 
outcome of Erk signaling changes very fundamental features of a cell, many levels of 
pathway modulation exist. Scaffolding platforms or proteins that bind and/or 
manipulate one of the pathway steps or ERK substrates can modify and fine-tune the 
outcome of Ras-Raf-MEK-ERK cascade signaling. Therefore the result of MAP kinase 
pathway activation can vary strongly between cell types and cell cycle stages and the 
organization of MAP kinase signaling in vivo takes place in an extremely complex 
manner (Fig.5.). 
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Fig.5. Simplified overview of the Ras signaling pathway. 
 
Mammals express 3 different isoforms of Raf, namely A-Raf, B-Raf and C-Raf [47]. All 3 
forms of Raf have 3 highly conserved domains, the carboxyterminal kinase domain and 
2 N-terminal regulatory domains, which are necessary for the binding to Ras and to 
several other proteins. Ablation of A-Raf in mice does not yield a developmental 
phenotype, but leads to neuronal defects in the adult mouse [48]. The individual 
function of A-Raf is not known so far, but B-Raf and C-Raf seem to be more crucial for 
Erk activation. Whereas B-Raf is not known to interfere with other signaling pathways, 
C-Raf can bind to and thereby inhibit Ask-1, MST-2 and Rok-αand  activate NF-κB.. C-
Raf ablation is embryonic lethal because of apoptosis of embryonic liver cells [49-51]. 
Knock-out of B-Raf is also embryonic lethal, due to vascular defects of the placenta 
[52-53]. B-Raf KO embryos supported by a wildtype placenta are born at term but die 
from severe neurodegenerative disease around postnatal day 21 [53]. 
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2.9. The Ras pathway in cancer 
 
The activity of the Ras-Raf pathway is frequently altered in human and murinecancers. 
In particular, activating point mutations of Ras   are found frequently in pancreatic 
cancer (58%), lung cancer (17%) and colon cancer (33%). In addition, activating 
mutations in B-Raf are frequent events in a subset of malignancies, such as melanoma 
(43%), thyroid cancer (39%) and colon cancer (12%) [54], although studies on mutation 
frequencies in human cancer must be treated with caution, since they are limited by 
sample numbers and by the possible statistically not representable choice of patients. 
The most frequent mutation is B-Raf V600E, which leads to a constitutively active B-Raf 
kinase with about 700-fold increase of kinase activity compared to wildtype [55]. On 
the contrary, mutations in C-Raf and A-Raf are extremely rare. 
Because of the high frequency of activating mutations, the pathway is a promising 
target for cancer therapy. Strategies to inhibit Ras and MEK have been designed. but 
have failed; in the case of Ras, inhibition of farnesylation, which is required for Ras 
activation, has been attempted but failed because this modification can be carried out 
by a number of redundant regulators. MEK inhibitors, on the other hand, have marked 
side effects, and therefore a reduced therapeutic window. Raf inhibition by Sorafenib 
is quite successful in the treatment of renal-cell carcinoma, most likely because of its 
anti-angiogenic properties. Second generation, more specific inhibitors of B-Raf are 
currently in clinical trials. PLX4032/RG7204 and GSK2118436 have showed a high 
response rate in patients, although in some patients new cancers arose. This paradox 
might be due to a transactivation of Raf dimers in cells that are wildtype for B-Raf [56]. 
Overall, the fact that the Ras-Raf pathway is a prime target of molecule-based 
strategies for cancer treatment stresses the need of  obtaining more knowledge about 
the essential functions of its component. 
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2.10. Knock-out of B-Raf in endothelial cells: B-Raf Tie2Cre mice 
 
Because B-Raf knock-out animals die from defects of the vasculature in the placenta, it 
is likely that B-Raf has a key function in endothelial cells [52-53]. To test this 
hypothesis, a mouse line, carrying two floxed alleles of B-Raf (exon 12 of the B-Raf 
gene is flanked by loxP sites) and expressing the Cre recombinase under the control of 
a Tie2 promotor (Tie2Cre) has been generated. Tie2 is expressed in endothelial as well 
as in hematopoietic cells, including macrophages, granulocytes, dendritic cells, B-cells, 
T-cells and NK cells [44, 57]. Deletion of B-Raf in B-Raf Tie2Cre mice was assessed by 
PCR and Western Blot. In endothelial cells the deletion of B-Raf is very efficient, 
whereas in bone marrow deletion efficiency varies. However, bone marrow cells 
stimulated with Lewis lung carcinoma (LLC-1) cell conditioned medium show increased 
expression of the Tie2 receptor, accompanied by more efficient deletion. This suggests 
that within the tumor environment, recombination of the floxed allele in bone marrow 
derived cells can be very efficient. Spleen lysates did not show significant deletion of B-
Raf, which indicates that B-cells and T-cells are not efficiently deleted. [Scherrer K., 
unpublished data or [58]] 
B-Raf Tie2Cre mice do not show any gross defects in development or  later in life, 
suggesting that B-Raf is not essential for tissue or vessel homeostasis.. Tissue 
architecture is normal and the number of blood vessels in different tissues is also 
unaffected. To monitor pathologic neo-vascularization, LLC-1 cells were injected 
subcutaneously and tumor growth in B-Raf Tie2Cre mice was measured. Surprisingly, 
endothelial B-Raf ablation accelerated tumor growth. Proliferation and apoptosis were 
unchanged but necrosis was significantly reduced at later stages of tumor progression 
in the tumors growing in the B-Raf deficient animals [Scherrer K., unpublished data]. 
Endothelial B-Raf ablation did not affect the density of tumor-associated vessels; in 
addition, primary B-Raf-deficient endothelial cells did not show any defects in 
sprouting, migration and proliferation in in vitro assays [58]. 
In this work, we investigated the phenotype of B-Raf Tie2Cre mice in detail to unravel 
the mechanism underlying accelerated LLC-1 tumor growth. We wanted to know 
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which properties of blood vessels are altered in the B-Raf Tie2Cre mice and how these 
changes lead to accelerated allograft growth. To address this question we investigated 
the functionality of vessels, measured by the extent of perfusion, the pericyte 
coverage and the vessel permeability. In addition, we wanted to investigate whether 
the function of B-Raf was endothelial cell-autonomous, or whether myeloid cells, also 
B-Raf-deficient in our model system, contributed to the phenotype.  
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3. Results 
 
3.1. B-Raf Tie2Cre mice show accelerated tumor growth 
 
To verify the phenotype of B-Raf Tie2Cre mice we repeated the injection of Lewis lung 
carcinoma (LLC-1) cells to study allograft tumor growth. The tumor cells were injected 
subcutaneously into the flank of B-Raf F/F Tie2Cre mice and B-Raf F/F mice as a 
control. As already shown, the mice with endothelial cell specific B-Raf deletion (B-Raf 
EC KO) showed accelerated tumor growth compared to the control mice (Fig.6.a). 
Further analysis of the data revealed a large difference in the growth of tumors 
implanted in male versus female host, irrespective of the host genotype. Tumors from 
male B-Raf EC KO mice showed significant larger tumor volume and weight compared 
to control. Tumors implanted in females generally reached only about half the size of 
those implanted in males. Tumor growth was accelerated in B-Raf EC KO compared to 
wild-type females, but the difference was not significant (Fig.6.b,c). Therefore, only 
male animals were used for further analyses and experiments.  
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Fig.6. Growth curves of subcutaneous LLC-1 allograft tumors in B-Raf Tie2Cre and 
control mice. Tumor volume was calculated by measuring length and width of the 
tumor with a caliper. a. Tumor growth curve in male and female animals, compared 
with  growth in male animals (b; right panel shows the tumor weight at day 16 post-
implantation)  or growth in female animals (c). 
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3.2. B-Raf EC KO tumors have the same quantity of vessels as control tumors 
 
Tumors isolated from B-Raf EC KO or wild-type mice were either embedded in paraffin 
or frozen in a medium that provides a matrix ideal for cutting frozen sections for 
further analysis. Our main interest was the endothelial compartment, because at this 
point it was very likely that the tumors from B-Raf EC KO mice grew faster because of 
better vascularization. The number of vessels was similar in tumors isolated from B-Raf 
EC KO or wild-type animals. Vessel density was quantified by counting single vessels, 
visualized by the endothelial cell specific marker CD31 [59], in 2µm thick sections. To 
verify this, we additionally monitored the area of CD31+ vessels, to be sure that there 
is no difference in the extent of vascularization. To achieve this, we prepared 40 – 
50µm thick cryosections which allow visualization of vessel structure in a defined 3 
dimensional area.  The cryosections were stained with an CD31 antibody and whole z-
stack of images were acquired using a confocal microscope. The z-stacks can be 
projected along the y-axis into one picture, reconstructing the structure of a vessel in a 
certain area with up to 40µm thickness. Quantification of the area of CD31+ vessels in 
tumor sections with ImageJ showed no difference in vessel-occupied area within the 
tumors of B-Raf EC KO mice and control (Fig.7.a-b). Also the distribution between large 
and small vessels, judged by their area, did not vary between B-Raf EC KO and control 
(Fig.7.c). 
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Fig.7. CD31 positive vessels. a. Projected photo stack of B-Raf EC KO tumor section 
(right) and control (left) labeled with a CD31 antibody. b. Quantification of CD31 
positive area per picture. c. Quantification of the distribution of vessels in large 
(ImageJ: vessel area in picture >6%) and small (ImageJ: vessel area in picture <6%).  
 
 
3.3. B-Raf EC KO tumors have the same number of perfused vessels as control 
 
The tumors of B-Raf EC KO tumors are larger than control and show less necrosis. This 
led to the assumption that they might be better supplied with nutrients and oxygen. 
Since the number of blood vessels was the same, maybe the quality of the B-Raf EC KO 
tumor vessels was improved. This would mean a normalized vasculature, optimally 
providing the tumor with oxygen. We wanted to investigate if the number of perfused 
vessels, i.e. of the vessels actively connected to the blood circulation of the animal, 
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was increased in B-Raf EC KO tumors. Therefore we injected a fluorescence-labeled 
lectin, which binds specifically to endothelial cells, in the orbital plexus of tumor 
bearing mice. This technique visualizes only functional, actively perfused vessels, in 
contrast to the CD31 staining, which labels all endothelial cells. Using this staining, we 
could conclude that the total quantity of perfused vessels in tumor growing in B-Raf KO 
EC and wild-type animals was similar. Vessel density in highly perfused areas mainly 
located at the border of the tumor, an indicator for invasion of blood vessels into the 
tumor and/or more indirect for the extent of branching and network formation, was 
also similar in control and B-Raf KO EC mice (Fig.8.). 
 
 
Fig.8. Vessel functionality. a. Projected image stack of tumors implanted in B-Raf EC KO 
(right) or control (left) mice. The vessels were labeled with FITC-Lectin. b. Quantification 
of the FITC-Lectin positive area in the whole section. c. Quantification of vessel density. 
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3.4. B-Raf EC KO tumors have the same extent of pericyte coverage as control 
 
Next, we wanted to assess the pericyte coverage of tumor blood vessels. It is possible, 
that vessels in the B-Raf EC KO tumors are normalized in comparison to control 
because of more pericytes associated with endothelial cells. Pericytes stabilize the 
vasculature and are important for the regulation of vessel functionality, steady blood 
flow and quiescence of endothelial cells. We performed a double staining on frozen 
sections with CD31 and NG2, a marker specific for pericytes. The area of pericytes in 
close proximity to CD31+ blood vessels, was calculated and expressed as % pericyte 
coverage. We found no difference in the number of pericytes associated with vessels 
in tumors growing in B-Raf EC KO and control mice (Fig.9.a-b). 
A more detailed analysis, performed by grouping the vessels according to their size, 
showed that vessels were covered with a higher number of pericytes, but failed to 
reveal any difference between B-Raf EC KO and control vessels (Fig.9.c). 
The vessels were further categorized in 3 classes, according to their extent of pericyte 
coverage (less than 5% coverage, between 5 and 15% coverage and more than 15% 
coverage) to monitor the contribution of vessels to each subclass in KO and WT. In B-
Raf EC KO, as well as in control mice, the class of vessels with 5 – 15% pericyte 
coverage was the largest, followed by less than 5% coverage and more than 15% 
coverage (Fig.9.d). The pericyte coverage of B-Raf EC KO tumor-associated vessels can 
therefore be considered as unchanged compared to control. 
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Fig.9. Pericyte coverage of tumor blood vessels. a. Projected stack of tumor sections 
isolated from B-Raf EC KO (lower picture) and control mice (upper picture) labeled with 
CD31 and NG2 antibodies to stain endothelial cells and pericytes, respectively. b. 
Quantification of the area of EC associated pericytes. c. Quantification of the area of EC 
associated pericytes specified for small and large vessels. The size of vessels is given in 
pixel. A vessel with an area below 1000pix2 is considered as a small vessel, in contrast 
to a large vessel with more than 1000pix2. One pixel is 1,85x10-4 mm. d. Quantification 
of the distribution of blood vessels according to their degree of pericyte coverage. 
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3.5. B-Raf EC KO mice show reduced VEGF stimulated permeability 
 
Taking together the similar numbers of perfused vessel and the similar pericyte 
coverage, vessel functionality didn’t seem enhanced in B-Raf EC KO mice so far. As the 
next parameter, we analyzed the permeability of blood vessels, since it is known that 
tumor-associated vessels in general show abnormally high permeability. We 
performed a Miles Assay that measures vessel permeability as a response to a stimulus 
such as VEGF. First, we injected Evans blue dye retroorbitally into mice. The dye enters 
the circulation and remains in the blood vessels, except at sites with decreased barrier 
function. We then stimulated permeability by intradermal injection of VEGF or PBS as a 
control. The dye leaking out of the vessel at the injection site is a measure of the 
permeability induced by the stimulus. We quantified leakage of Evans blue by 
measuring absorption with a spectral photometer after excising the skin and extracting 
the dye.  
The total value of Evans blue extracted from the PBS injection site, reflecting the 
permeability of vessels without any angiogenic stimulus, was not significantly different 
in B-Raf EC KO mice and control mice (Fig10.a). VEGF induced permeability was 
calculated by subtracting the PBS-induced leakage from the amount of Evans blue 
leaked from the VEGF injection site, to minimize the influence of differences in general 
permeability, which were quite high between individuals. In control mice, the VEGF 
injection stimulated permeability 2.5-fold. The B-Raf EC KO mice in contrast showed 
only about 1.4-fold induction (Fig10.b-c).  This result was barely significant (p = 
0,0511), and showed a strong trend that led to further investigation of vessel 
permeability in the B-Raf EC KO animals. 
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Fig.10. Miles Assay. a. Total PBS induced permeability. b. Relative VEGF induced 
permeability. c. Evans blue dye leaking out of skin from B-Raf EC KO animals (right) and 
control animals (left) after intradermal injection of PBS and VEGF, respectively. 
 
 
3.6. B-Raf EC KO mice show reduced permeability in tumors 
 
To further investigate whether reduced permeability, and therefore vessel 
normalization, could be the reason for the accelerated tumor growth in B-Raf Tie2Cre 
mice, we assessed permeability directly in tumor tissue by injecting Evans blue dye in 
tumor bearing B-Raf EC KO and control mice and calculating the amount of dye leaking 
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out relative to the weight of the tumor. As a control, we quantified vessel permeability 
in liver and lung. We found significantly reduced blood vessel permeability in the 
tumors  developing in B-Raf EC KO animals compared to control, whereas in the 
control organs there was no difference (Fig.11.). This result indicates that the vessels 
of the B-Raf EC KO animals are less permeable specifically in the tumor, where we have 
an environment with abnormally high concentrations of pro-angiogenic factors. Less 
permeable vessels could be beneficial for tumor growth, because normalization of the 
tumor vasculature could help deliver nutrients and oxygen more efficiently especially 
to inner parts of the tumor.  
 
 
Fig.11. Quantification of Evans blue extraction from liver and tumor from B-Raf EC KO 
animals and control animals. 
 
 
3.7. B-Raf KO ECs show reduced VEGF stimulated permeability in vitro 
 
To verify the in vivo results from the experiments with Evans blue dye, we analyzed 
permeability of endothelial cells in vitro. We isolated primary mouse lung endothelial 
cells from B-Raf EC KO mice and control. For the permeability assessment we used a 
real-time cell analyzer that measures the impedance of a monolayer of cells. The 
impedance changes according to the electrical resistance generated by the monolayer, 
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which in turn is dependent on cell-cell contacts. Loosening or strengthening of cell-cell 
contacts in a monolayer of endothelial cells resembles what we call permeability in 
vivo, therefore the impedance measurement provides direct information about 
permeability under the right conditions. For this assay we used primary endothelial 
cells as well as immortalized ECs. 
Monolayer formation was monitored by eye using a microscope. Permeability-
enhancing stimuli were added to the cells while impedance measurement was 
performed every 15 seconds. As a result, we could show the reaction of the cells to the 
stimuli as well as the recovery in real-time.  
The unstimulated monolayer of B-Raf KO and control cells did not show any difference 
in general barrier function. After stimulation with VEGF endothelial cells normally 
loosen their cell-cell contacts and therefore permeability is enhanced. This effect was 
clearly evident in real-time cell analyzer. In the curve (Fig.12.e) the Cell Index, which is 
a unit-less quantity the software calculates from the impedance, decreases after 
stimulation with VEGF. This means that the monolayer becomes more permeable. The 
primary B-Raf KO ECs, and even more prominently the immortalized ECs show a 
significant disability to react to VEGF with increased permeability (Fig.12.a and b+e). B-
Raf KO ECs do not show any problems to react to other stimuli such as Thrombin that 
also enhances permeability of endothelial cells by elevating intracellular Ca2+ levels 
achieved by the activation of various signaling pathways that are partially the same 
and partially different than the pathways activated by VEGF signaling [60] (Fig.12.c-d). 
This indicates a selective defect of B-Raf KO ECs in reacting to VEGF, whereas other 
stimuli elicit a normal response. 
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Fig.12. In vitro permeability assay. a-d. Permeability of isolated primary endothelial 
cells (a+c) and immortalized endothelial cells (b+d) treated with different stimuli. e. 
Example of a graph showing impedance measurement by the real-time cell analyzer. A 
monolayer of immortalized cells was treated with VEGF or PBS respectively, impedance 
was measured every 15 seconds after 1h of stimulation. Cell Index is a unit-less 
quantity calculated directly from the impedance and provides direct information about 
the permeability of the monolayer.  
 
 
  
 
35 
3.8. B-Raf knock-out in myeloid cells does not affect LLC-1 tumor growth 
 
Tie2Cre recombinase deletes not only in endothelial cells, but also in hematopoietic 
cells. Therefore, B-Raf deletion also occurs in myeloid cells (macrophages, dendritic 
cells and granulocytes), T- and B-Lymphocytes, and NK cells [61], all of which can have 
a strong impact on tumor growth. Macrophages especially can influence tumor growth 
positively or negatively [41-42, 62], and have an impact on tumor angiogenesis [44, 
46]. Therefore it is very important for us to investigate whether macrophages play a 
role in our system and if so, how much they contribute to the phenotype of 
accelerated tumor growth in B-Raf Tie2Cre mice. 
To investigate the impact of the deletion of B-Raf in macrophages, we crossed a 
LysMCre transgenic line, expressing a Cre recombinase active only in the myeloid 
compartment [63], with B-Raf F/F mice and obtained offspring (B-Raf myeloid cell (MC) 
KO) with a myeloid-specific knock-out of B-Raf, as demonstrated by PCR of peritoneal 
macrophages. LLC-1 tumor allografts injected in these mice were indistinguishable in 
volume and weight from those implanted in wild-type animals (Fig.13), indicating that 
myeloid B-Raf does not have a crucial function in LLC-1 tumor growth in our system. 
We had no opportunity to investigate lymphocytes and NK cells, therefore the impact 
of B-Raf in those cells is unknown. In addition we made no distinction between 
lymphatic endothelial cells and blood vessel endothelial cells. Taken together, the 
results obtained in vivo with the B-Raf EC and B-Raf MC KO and the results obtained in 
vitro with B-Raf deficient endothelial cells are consistent with the hypothesis that 
accelerated tumor growth results from the knock-out of B-Raf in endothelial cells, 
leading to vessel normalization. 
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Fig.13. a. Growth of subcutaneous LLC-1 allograft tumors in B-Raf LysMCre and control 
mice. Tumor volume was calculated after measuring length and width of the tumor 
with a caliper. b. Tumor weight at day 19 after dissection of tumors. 
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4. Discussion 
 
This work focused on the function of B-Raf in tumor-associated endothelial cells. 
Conventional deletion of B-Raf results in embryonic lethality due to reduced VEGF 
production and vascularization in the placenta[53]. To investigate whether B-Raf has 
an essential function in endothelial cells we worked with a conditional knock-out, the 
B-Raf EC KO mice. These mice lack apparent phenotypes unless challenged with 
allograft LLC-1 tumors, which grow faster in B-Raf EC KO animals of injected cells. The 
allografts are larger than those grown in control mice, and contain less necrotic area 
despite having the same number of blood vessels. We therefore hypothesized that the 
B-Raf EC KO tumors are better supplied with nutrients and oxygen, which, in turn, 
could be explained with enhanced functionality of the B-Raf EC KO vessels. 
 
Neither active perfusion of tumor vessels by blood circulation nor pericyte coverage 
were altered in the B-Raf EC KO mice. However, skin blood vessels of the B-Raf EC KO 
mice were less capable of reacting to a VEGF injection by increasing permeability than 
vessels of the control mice. More importantly, the tumor vessels of B-Raf EC KO mice 
were less permeable than the control tumor vessels; consistent with these in vivo data, 
B-Raf-deficient endothelial cells were not able to react to VEGF stimulus with increased 
permeability to the same extent as control cells. These data indicate that the enhanced 
allograft growth observed in B-Raf EC KO mice is due to decreased EC permeability, 
which leads to vessel normalization.  
Tie2Cre is active in both endothelial cells and bone marrow, and macrophages have 
been proposed to play an important role in vessel stability, by secreting VEGF [64]. The 
Baccarini lab has previously shown that B-Raf and ERK are necessary for VEGF 
production in a model of insulinoma [65]. We therefore investigated the involvement 
of macrophages in the growth of LLC-1 allografts in a mouse line lacking B-Raf in 
myeloid cells; tumors developed normally in these mice indicating that B-Raf ablation 
in myeloid cells does not contribute to the phenotype observed in the B-Raf EC KO 
system.  
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We observed a significant difference in LLC-1 allograft growth between sexes 
irrespective of the host genotype. There are many reports on the impact of sex 
hormones on tumor growth, but those studies usually concentrate on hormone-
dependent cancers affecting breast, endometrium, ovary and prostate [66]. In non-sex 
hormone-dependent cancers the impact of sex is not determined. For adeno-
carcinomas it is reported that estrogen has a tumor promoting role in a mouse model 
[67]. In humans, estrogen can be a risk factor for cancer development or have a 
protecting effect against cancers such as hepatocellular carcinoma [68]. The latter 
effect is based on the anti-inflammatory effects of estrogens, namely the down-
regulation of IL-6 in macrophages [69]. Other studies have shown that females are less 
susceptible to cancer development in tissues that are not conventional targets of sex 
hormones [70]. 
However, for LLC-1 allografts in mice there is no reported influence of sex on tumor 
growth. So we can only speculate that female animals are protected against 
inflammation by estrogens in our model and therefore tumor growth is delayed.  
 
Taken together, our findings indicate that under pathological conditions endothelial 
cell B-Raf contributes to a state of hyperpermeability of tumor-associated blood 
vessels caused by VEGF (Fig.14). According to this theory, B-Raf EC KO mice show an 
accelerated tumor growth because the tumor blood vessels are less leaky and 
therefore abler to provide the tumor  with nutrients and oxygen [64, 71].  
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Fig.14. Current working model. 
 
Mechanistically, we can only speculate how the regulation of permeability via B-Raf 
occurs. Most likely Erk is the key player downstream of B-Raf, since Erk is known to be 
upregulated downstream of VEGF signaling [72]. 
Several studies have shown that downregulation of Erk in endothelial cells can lead to 
decreased permeability. Breslin et al. has published that VEGF increases permeability 
in HUVECs and that this increase is attenuated by pretreatment with a MEK inhibitor 
and abolished by depletion of Erk. [73]. Similar experiments with bovine lung 
microvascular endothelial cells (BLMVECs) support the theory of MEK and Erk playing a 
role in hyperpermeability caused by 4-HNE, a product generated in the cell after 
oxidative stress [74]. In vivo, it has been demonstrated that exposure of mice to 
aerosols containing the bacterial endotoxin LPS enhances permeability of pulmonary 
vessels in an indirect manner by stimulating different cell types in the lung to produce 
permeability enhancing factors, such as cytokines and VEGF. Increased permeability 
correlates with Erk activation in the lung and can be reduced by co-administration of a 
MEK inhibitor. The fact that phosphorylated Erk was found at cell-cell borders after 
VEGF treatment strengthens the hypothesis that VEGF-mediated permeability 
enhancement is caused by Erk dependent myosin2 activation, leading to actin 
cytoskeleton rearrangements and to the disruption of cell-cell contacts [75].   
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These studies all highlight the importance of Erk and MAP kinase signaling in 
hyperpermeability induced by different stimuli. Assuming that in endothelial cells, as in 
other cells [53, 65, 76], B-Raf is the essential activator of MEK, a similar mechanism 
could underlie the decreased permeability of B-Raf-deficient vessels and monolayers.  
Decreased intratumoral permeability may also lead to a partial normalization of the 
tumor-associated vasculature similar to the one achieved, at least in a small time 
window, by inhibiting VEGF [77], under which conditions blood flow, pericyte coverage 
or increased permeability were improved [21, 77].  Although we could not observe 
improvement of other blood vessel parameters such as increased perfusion or better 
pericyte coverage, in future it would be interesting to investigate whether tumors 
grown in B-Raf EC KO mice have also improved responsiveness to chemoradiation 
therapies. In fact, vessel normalization has been shown to increase tumor growth in 
some cases [64, 71], but decreases the metastatic potential of tumor cells [21]. 
Possible explanations for this phenomenon are  reduction of interstitial pressure, 
acidosis and hypoxia in the tumor; and a block of tumor cell dissemination through 
improved endothelial barrier function. It would be interesting to examine if the 
endothelial deletion of B-Raf alters the metastatic behavior of LLC-1 cells in the mice. 
 
The newly identified function of B-Raf in the tumor-associated vasculature could be of 
special relevance in tumor therapies where B-Raf inhibitors are already in use. Several 
studies with animal models as well as clinical studies in patients have shown that B-Raf 
inhibitors significantly increase therapeutic effect of other drugs, if they are 
administered as a combined treatment. Augustine et al. showed that the kinase 
inhibitor Sorafenib, that inhibits Raf amongst other kinases, significantly enhances the 
effect of chemotherapeutic drugs melphalan and temozolomide [78]. In a phase II 
clinical study sorafenib has been administered in combination with dacarbazine, which 
also led to a significantly increased therapeutic effect [79]. 
The underlying mechanism for the increased efficacy of chemotherapeutics 
administered in combination with Sorafenib is incompletely understood. Partially, the 
inhibition of MAP kinase signaling is responsible for the therapeutic benefits in 
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combined treatment [78]. Our results now show a normalization of tumor vasculature 
after deletion of B-Raf in endothelial cells. Although tumor growth is accelerated after 
the deletion of B-Raf in our mouse model, co-administration of chemotherapeutic 
drugs that target growth of cancer cells and inhibition of B-Raf in endothelial cells 
could lead to partial normalization of the tumor-associated vasculature, leading to 
better drug delivery and uptake in the tumor and ultimately to more effective tumor 
shrinkage. 
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5. Methods 
 
Mice 
 
All animal experiments were performed in accordance with a protocol authorized by the 
Austrian Ministry of Science and Communications, following the approval by the national 
Ethical Committee for Animal Experimentation. 
Mice with endothelial and hematopoietic cell-restricted B-Raf deletion were obtained by 
crossing B-Raf flox/flox mice (F/F), in which B-Raf Exon 12 is flanked with LoxP sites, with mice 
expressing the Cre recombinase under the control of the Tie2 promoter[57]. Mice with 
myeloid cell-specific B-Raf deletion were obtained by crossing B-Raf F/F mice with mice 
expressing the Cre recombinase under the control of lysozyme M (LysM) promoter[63]. All 
experiments were performed using only mixed backround (129/Sv and C57BL/6; F1) male mice 
of 8 – 10 weeks of agewith. 
 
 
EC isolation and culture 
 
To obtain pure cultures of primary mouse endothelial cells (ECs) we isolated ECs from 
the lung, an organ ideal for EC isolation because of its high number of microvascular 
endothelial cells. The isolation was performed according to the protocol of Wimmer et 
al. (submitted manuscript). In brief, 5 – 13 days old mice were sacrificed, their lungs 
were excised, placed in cold EC Base Medium and quickly transferred to a cell culture 
dish. The lungs were minced with scissors and digested in 1 mg/ml Collagenase Type 1 
(Worthington) for 1h at 37°C. Tissue clumps were crushed by passing the suspension 
through a 18G needle. To obtain single cells, the suspension was filtered through a cell 
strainer (70 μm mesh size; BD Falcon) prior to seeding on a cell culture dish pretreated 
with 2% gelatin (Sigma) and 10 μg/ml Fibronectin (Roche). The plates were washed 
with phosphate buffered saline (PBS) after 24 hours. 
2 days after seeding the cells were incubated with dynabeads (Dynal Biotech) coated 
with anti-mouse ICAM-2 antibody (BD-Pharmingen) for 1h at 4°C. Cell‐coated beads 
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were placed for 2 min in a Magnetic Particle Concentrator (Dynal), washed 4 times 
with EC Base Medium and seeded. The sorting procedure was repeated once after 2 
more days. 
Primary cells were cultured in EC Culture Medium and seeded on pretreated plates 
(2% gelatin (Sigma) and 10 μg/ml Fibronectin (Roche) over night at 37°C). 
The immortalized cells were generated according to the protocol from Wimmer et al. 
(submitted manuscript) and cultured in EC Base Medium. 
 
20x PBS: 180g NaCl, 6,4g NaH2PO4 and 21g Na2HPO4 were dissolved in 1l double-
destilled Water (ddH2O). pH was adjusted to 7,2 – 7,4 with HCl. 
 EC Base Medium: DMEM Medium supplemented with 1mM non‐essential amino 
acids, 1mM sodium pyruvate (Gibco), 25 mM HEPES pH 7.4 (Applichem), 20% FBS 
(Sigma), 0,1g/l streptomycin and 0,06g/l penicillin. 
EC Culture Medium: EC Base + 100 μg/ml Endothelial Mitogen (Biomedical 
Technologies Inc) and 100 μg/ml Heparin (Sigma). 
 
 
Isolation of peritoneal Macrophages 
 
To verify the deletion of B-Raf in macrophages of B-Raf LysMCre mice, we isolated 
macrophages from the peritoneal cavity of 7 weeks old mice injected intraperitoneally 
with 1ml Peptone (3% in H2O), which leads to the accumulation of peritoneal 
macrophages.  5 days after injection, the mice were sacrificed . and their abdominal 
skin was carefully peeled back to expose the peritoneum. 10ml DMEM were injected 
carefully in the abdominal cavity and a peritoneal lavage was performed. The medium 
procedure was repeated once. The macrophages were pooled, centrifuged (300g, 
5min) and cultured in Mφ culture medium. After cultivation the medium of the cells 
needs to be replaced every 6 to 12 hours for 1 day. 
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Mφ culture medium:  DMEM medium supplemented with 10% FCS (Sigma), 10% Lcell 
conditoned medium (the filtered, cell-free supernatant of L929 mouse fibroblast cell 
line, which contains growth factors necessary for macrophage growth),  0,1 g/l 
streptomycin and 0,06g/l penicillin. 
 
 
LLC-1 Allografts 
 
For the tumor allograft experiments, injection of Lewis lung carcinoma cells (LLC-1), a 
well characterized laboratory mouse cancer cell line, was performed. LLC-1 cells were 
cultured in DMEM medium supplemented with 10% FBS (Sigma). No antibiotics were 
used to avoid indirect effects on the mouse after injection of the cells. To obtain 
subcutaneous tumor allografts in mice, 106 LLC-1 cells in 100µl PBS were injected 
subcutaneously into 8-10 weeks old male mice of mixed background (SV129/Bl6, F1) . 
The size of the arising tumors was measured every 2-3 days with a caliper, starting 7 
days after injection of LLC-1 cells. Tumor volume was calculated according to the 
spheroid formula :  V=0,523*w2*l (w= tumor with; l= tumor length). 16 days after 
implantation, the tumors were dissected and fast frozen in O.C.T. cryo compound 
(Tissue Tek), a premixed embedding medium ideal for frozen cutting, and stored at -
20°C until further analysis. 
 
 
FITC-Lectin injection 
 
Functionality of tumor blood vessels was assessed by staining vessels connected to 
blood circulation of the animal with fluorescent labeled tomato lectin (FITC lectin) 
binding specifically to endothelial cells. FITC lectin (Vector Laboratories, 50µl of 
2mg/ml solution) was injected retroorbitally into tumor-bearing mice 16 days after 
LLC-1 cell implantation. The mice were sacrificed 20min later and perfused with 20ml 
PBS followed by 20ml 4% paraformaldehyde (PFA) through the left heart ventricle. 
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Tumors and control tissue were fast frozen in O.C.T. cryo compound (Tissue Tek) on 
dry ice and stored at -20°C. 
40-50µm thick sections were cut on a cryotome (MICROM HM 500 OM), placed on 
microscope slides (Thermoscientific Menzel-Glaeser Superfrost Plus) and air-dried for 
20min in the dark. The tissue was fixed in 4% paraformaldehyde (PFA) for 1h, mounted 
(DAKO fluorescent mounting medium), sealed with a cover slip (Marienfeld Laboratory 
glassware) and dried overnight. The slides were inspected and imaged using a Confocal 
Microscope (Zeiss LSM Meta). 
 
PFA solution 4%: 80g PFA with 2 – 4 NaOH pellets was dissolved in PBS at 56°C. The pH 
was adjusted to 7,2 with HCl and the final volume was 2l. Before use, the PFA solution 
needed to be filtered to get rid of insoluble remnants. 
 
 
Miles Assay and Evans blue extraction from tumor 
 
For analysis of permeability of skin blood vessels, the Miles Assay was performed 
according to previous described protocols [80]. In brief, Evans blue (1% in PBS, Sigma-
Aldrich), a dye binding to plasma proteins and leaking out with them at sites of 
hyperpermeability, was injected retroorbitally in 12 weeks old male mice of mixed 
background (SV129/Bl6 F1) . 10min later, VEGF (R&D Systems, 50ng in 40-50µl PBS) or 
PBS were injected intradermally on either side of the flank. 20min later the mice were 
sacrificed and the skin of the injection sites was incubated in 2ml Formamide. The 
liver, used as a control organ, was incubated in 3ml Formamide. 4 days incubation at 
RT extracts the dye which can be measured directly by spectral photometry at 620nm 
wavelength. 
Alternatively, tumor-bearing mice were injected retroorbitally with Evans blue 16 days 
after LLC-1 cells implantation. The mice were sacrificed 30min after injection and 
tumors and livers were isolated and placed in 3ml of Formamide. The extracted dye 
was calculated relative to tissue weight. 
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Immunofluorescence double staining for endothelial marker CD31 and pericyte 
marker NG2 
 
We used frozen tumors for a double staining of endothelial cells (CD31 antibody) and 
pericytes (NG2 antibody) to monitor the pericyte coverage of blood vessels. 40-50µm 
thick sections were cut on a cryotome (MIRCROM HM 500 OM), dried 20min at RT and 
fixed with 4%PFA for 1h. Epitopes were retrieved by treatment with protease type XIV 
(Sigma cat nr.: P5147; 3,5U/ml for 8min,), followed by blocking of the endogenous 
peroxidase with 1.5% H2O2 for 40min. The slides were then blocked with blocking 
solution (normal goat serum NGS, Vector laboratories, cat nr.: s-1000, 0,5% in PBS) for 
30min and incubated with rat anti-mouse CD31 (BD Pharmingen cat nr.: 550274; 1:50 
in blocking solution) and rabbit anti-mouse NG2 (Millipore cat nr.: AB5320; 1:200 in 
blocking solution) overnight at 4°C. The slides were then incubated with the secondary 
antibody against CD31, horseradish peroxidase (HRP)-conjugated anti-rat (Amersham 
cat nr.: BA-4000, 1:1000 in blocking solution), for 1h at RT. The HRP signal was 
amplified using the Tyramide signal amplification TSA kit (PerkinElmer). The TSA 
reagent is a fluorophore-labelled tyramide, multiple copies of which are activated by 
the HRP moiety conjugated to the secondary antibody. The resulting short-lived 
tyramide radicals covalently bind to to residues in the vicinity of the HRP–target 
interaction site, leading to signal accumulation in the proximity of the antigen. . The 
slides were incubated with TSA green, a TSA reagent coupled to fluorescein, (1:100 in 
amplification diluent provided with the kit) for 10min at room temperature (RT) . The 
remaining HRP was inactivated using 5% H2O2 for 40min at RT. The secondary antibody 
against NG2, anti-rabbit HRP, was then applied for 1h at RT. In this case, the signal was 
amplified using TSA red, a TSA reagent coupled to tetramethylrhodamin, (1:100 in 
amplification diluent) for 10min at RT. DNA was stained with DAPI (1:3000 in PBS, 
10min at RT) and the slides were mounted in a drop of fluorescent mounting medium 
(Dako) to reduce bleaching of the fluorophores and left to dry overnight. Between 
each of the steps, except after blocking, the slides were washed with TNT buffer (TSA 
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kit, PerkinElmer). The slides were inspected and imaged by confocal Microscopy using 
aZeiss LSM Meta. 
20x TNT buffer (recipe from TSA kit, PerkinElmer): 242,28g Tris and 175,32g NaCl were 
dissolved in ddH2O. The pH was adjusted to 7,5 with HCl and the final volume was 1l. 
 
 
Real-time cell analysis 
 
For real-time analysis of cell function we used the xCELLigence RTCA SP system (Roche) 
and the associated software (Roche). The real time cell analyzer (RTCA) measures 
electrical impedance (Ζ) across microelectrodes integrated into the bottom of special 
tissue culture plates (E-PLATES). Cells attaching to the plate on top of the electrodes 
lead to an increase in electrode impedance. The larger the area of the plate covered 
with cells, the stronger is the increase in impedance. The measurement is carried out 
over a defined time period and results in a curve that represents the biological status 
of the cells. Depending on the setup of the experiment, impedance measurement can 
give information about cell growth, morphology or adhesion. We used the RTCA to 
analyze barrier function of a monolayer of endothelial cells. An unstimulated, 
confluent monolayer of ECs generates stable electrical impedance. Addition of a 
permeability enhancing stimulus to the cells leads to loosening of cell-cell contacts 
resulting in a drop in electrical resistance that is measured in real-time by the RTCA. 
10,000 immortalized ECs or 15,000 isolated primary ECs were seeded in one well of the 
E-PLATE VIEW 96 (Roche) respectively. For each condition, quadruplicates were 
performed. the RTCA measured impedance Overnight every 30min, yielding 
information on cell-substrate adhesion and cell-cell adhesion. After a period of about 
12 hours the cells formed a monolayer yielding stable impedance measurements. 
Monolayer formation. was verified microscopically.  Before addition of a stimulus the 
interval of impedance measurement was adjusted to 15 seconds, the shortest possible 
interval. VEGF (500ng/ml, R&D Systems cat nr.: V7259), Thrombin (10U/ml, Sigma-
Aldrich cat nr.: T4648), or PBS as a control were added to all quadruplicate wells at 
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once using a multichannel pipette. The impedance measurement was continued for at 
least 3 hours after stimulus addition until the barrier function was clearly not 
decreasing any more.  
 
 
Statistical Analysis 
 
P values were calculated using the two‐tailed Student's t test. A p value ≤ 0.05 is 
considered statistically significant. Each experiment was repeated at least 3 times. For 
experiments with mice, at least 4 animals per genotype and condition were used. 
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